Kezar Life Sciences (NASDAQ:KZR) Sees Large Volume Increase – Here’s What Happened

Kezar Life Sciences, Inc. (NASDAQ:KZR) shares saw an uptick in trading volume on Thursday . 47,512 shares were traded during mid-day trading, a decline of 36% from the previous session’s volume of 74,244 shares.The stock last traded at $7.52 and had previously closed at $8.19.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Kezar Life Sciences in a research note on Monday, October 14th.

Kezar Life Sciences Trading Down 9.2 %

The company has a 50 day simple moving average of $6.88 and a two-hundred day simple moving average of $6.89. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.58 and a current ratio of 9.58. The company has a market cap of $541.15 million, a PE ratio of -5.37 and a beta of 0.21.

Kezar Life Sciences (NASDAQ:KZR) last issued its earnings results on Tuesday, August 13th. The company reported ($2.80) EPS for the quarter, beating analysts’ consensus estimates of ($3.20) by $0.40. Sell-side analysts forecast that Kezar Life Sciences, Inc. will post -1.2 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of KZR. Stonepine Capital Management LLC bought a new stake in Kezar Life Sciences in the second quarter worth $630,000. BNP Paribas Financial Markets grew its holdings in Kezar Life Sciences by 35.4% during the first quarter. BNP Paribas Financial Markets now owns 273,430 shares of the company’s stock valued at $247,000 after purchasing an additional 71,543 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Kezar Life Sciences by 1.0% in the first quarter. Vanguard Group Inc. now owns 3,094,224 shares of the company’s stock worth $2,790,000 after buying an additional 30,740 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Kezar Life Sciences by 42.5% during the 1st quarter. Acadian Asset Management LLC now owns 1,790,838 shares of the company’s stock worth $1,613,000 after buying an additional 534,203 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Kezar Life Sciences in the 2nd quarter valued at $63,000. Institutional investors and hedge funds own 67.90% of the company’s stock.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.